Relevant bibliographies by topics / B-cell malignancie

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'B-cell malignancie'

Author: Grafiati
Published: 1 April 2023
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'B-cell malignancie.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "B-cell malignancie"

1

Miao, Miao, Wu Depei, Aining Sun, Ying Wang, Lingzhi Yan, and Qian Wu. "The Efficacy and Safety of Recombinant Human Thrombopoietin in Patients with Hematological Malgnancies After Allogeneic Hematopoietic Stem Cell Transplantation." Blood 118, no. 21 (2011): 4565. http://dx.doi.org/10.1182/blood.v118.21.4565.4565.

Full text
Abstract:
Abstract Abstract 4565 OBJECTIVE: To evaluate the efficacy and sefety of recombinant human thrombopoietin(rhTPO) prior to engraftment in adults with hematological malignancie who received allogeneic haematopoietil stem cell transplantation(Allo-HSCT). METHODS: This sutdy was a randomized, controlled clinical trial,38 patients were hematological malignancie, inclulding acute and chrinic myeloid leukemia, acute lymphoblastic leukemia, lymphoma.They received Allo-HSCT and were randomly divided into groups(group A 19 cases, group B 19 cases).The group A was no-rhTPO as control, the group B were re
APA, Harvard, Vancouver, ISO, and other styles
2

Lydyard, Peter M., Andrew P. Jewell, Christoph Jamin, and Pierre Y. Youinou. "CD5 B cells and B-cell malignancies." Current Opinion in Hematology 6, no. 1 (1999): 30. http://dx.doi.org/10.1097/00062752-199901000-00006.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Zweidler-McKay, Patrick A., Yiping He, Lanwei Xu, et al. "Notch signaling is a potent inducer of growth arrest and apoptosis in a wide range of B-cell malignancies." Blood 106, no. 12 (2005): 3898–906. http://dx.doi.org/10.1182/blood-2005-01-0355.

Full text
Abstract:
Although Notch receptor expression on malignant B cells is widespread, the effect of Notch signaling in these cells is poorly understood. To investigate Notch signaling in B-cell malignancy, we assayed the effect of Notch activation in multiple murine and human B-cell tumors, representing both immature and mature subtypes. Expression of constitutively active, truncated forms of the 4 mammalian Notch receptors (ICN1-4) inhibited growth and induced apoptosis in both murine and human B-cell lines but not T-cell lines. Similar results were obtained in human precursor B-cell acute lymphoblastic leu
APA, Harvard, Vancouver, ISO, and other styles
4

Brudno, Jennifer N., Robert P. T. Somerville, Victoria Shi, et al. "Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease." Journal of Clinical Oncology 34, no. 10 (2016): 1112–21. http://dx.doi.org/10.1200/jco.2015.64.5929.

Full text
Abstract:
Purpose Progressive malignancy is the leading cause of death after allogeneic hematopoietic stem-cell transplantation (alloHSCT). After alloHSCT, B-cell malignancies often are treated with unmanipulated donor lymphocyte infusions (DLIs) from the transplant donor. DLIs frequently are not effective at eradicating malignancy and often cause graft-versus-host disease, a potentially lethal immune response against normal recipient tissues. Methods We conducted a clinical trial of allogeneic T cells genetically engineered to express a chimeric antigen receptor (CAR) targeting the B-cell antigen CD19.
APA, Harvard, Vancouver, ISO, and other styles
5

Ren, Anqi, Xiqin Tong, Na Xu, Tongcun Zhang, Fuling Zhou, and Haichuan Zhu. "CAR T-Cell Immunotherapy Treating T-ALL: Challenges and Opportunities." Vaccines 11, no. 1 (2023): 165. http://dx.doi.org/10.3390/vaccines11010165.

Full text
Abstract:
T-cell acute lymphoblastic leukemia (T-ALL), a form of T-cell malignancy, is a typically aggressive hematological malignancy with high rates of disease relapse and a poor prognosis. Current guidelines do not recommend any specific treatments for these patients, and only allogeneic stem cell transplant, which is associated with potential risks and toxicities, is a curative therapy. Recent clinical trials showed that immunotherapies, including monoclonal antibodies, checkpoint inhibitors, and CAR T therapies, are successful in treating hematologic malignancies. CAR T cells, which specifically ta
APA, Harvard, Vancouver, ISO, and other styles
6

Hudecek, Michael, Thomas M. Schmitt, Sivasubramanian Baskar, et al. "The B-cell tumor–associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor." Blood 116, no. 22 (2010): 4532–41. http://dx.doi.org/10.1182/blood-2010-05-283309.

Full text
Abstract:
Monoclonal antibodies and T cells modified to express chimeric antigen receptors specific for B-cell lineage surface molecules such as CD20 exert antitumor activity in B-cell malignancies, but deplete normal B cells. The receptor tyrosine kinase-like orphan receptor 1 (ROR1) was identified as a highly expressed gene in B-cell chronic lymphocytic leukemia (B-CLL), but not normal B cells, suggesting it may serve as a tumor-specific target for therapy. We analyzed ROR1-expression in normal nonhematopoietic and hematopoietic cells including B-cell precursors, and in hematopoietic malignancies. ROR
APA, Harvard, Vancouver, ISO, and other styles
7

Chattaraj, Asmi, Mohammad Ebad Ur Rehman, Israr Khan, et al. "Safety and efficacy of allogeneic CAR-T cells in B-cell malignancies: A systematic review and meta-analysis." Journal of Clinical Oncology 40, no. 16_suppl (2022): e19530-e19530. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e19530.

Full text
Abstract:
e19530 Background: Immunotherapy with chimeric antigen receptor T (CAR-T) cells has proven effective in recent trials for patients with B cell malignancies, who relapsed after stem cell transplantation. Genetically modified allogeneic CAR T-cells used in advanced B cell malignancy engage with multiple target allo-antigens along with CD19 and/or CD20, leading to elimination of malignant B cells resulting in a potent graft versus malignancy effect with avoidance of tumor escape. Some concerns regarding their use exist like life-threatening graft-versus-host disease (GVHD) and rapid clearance by
APA, Harvard, Vancouver, ISO, and other styles
8

Tonino, Sanne H., Marinus H. J. Van Oers, Rene A. Van Lier, and Marie Jose Kersten. "CMV-Associated Expansion of CD8+CD45RA+CD27− T-Cells in Patients with B-Cell Malignancies." Blood 110, no. 11 (2007): 3592. http://dx.doi.org/10.1182/blood.v110.11.3592.3592.

Full text
Abstract:
Abstract In patients with various malignancies of B-cell origin, changes in the T-cell compartment have been observed. In B-cell chronic lymphocytic leukemia (CLL), we have previously described an expansion of T-cells, largely due to an increase in T-cells exhibiting the CD45RA+CD27- effector phenotype. This was found only in cytomegalovirus (CMV) seropositive patients, suggesting that CMV-antigen drives this expansion. Indeed a considerable fraction of these T-cells were shown to be CMV-specific. At present it is unknown whether this alteration of the T-cell compartment is specific for CLL or
APA, Harvard, Vancouver, ISO, and other styles
9

Incrocci, Ryan, Molly McCormack, and Michelle Swanson-Mungerson. "Epstein–Barr virus LMP2A increases IL-10 production in mitogen-stimulated primary B-cells and B-cell lymphomas." Journal of General Virology 94, no. 5 (2013): 1127–33. http://dx.doi.org/10.1099/vir.0.049221-0.

Full text
Abstract:
Epstein–Barr virus (EBV) latently infected B-cells are the precursors of EBV-associated malignancies. EBV-infection induces the production of pro-survival and anti-inflammatory cytokines that may be important in the transition between latency and malignancy. One EBV protein, LMP2A, can be detected in both latently infected resting B-cells and in EBV-associated malignancies. Therefore, we tested the ability of LMP2A to influence cytokine production using both LMP2A-Tg primary B-cells and LMP2A-expressing B-cell lines. Our data demonstrate that LMP2A does not globally alter B-cell-produced cytok
APA, Harvard, Vancouver, ISO, and other styles
10

Prakash, Ajay, and Alhossain A. Khalafallah. "Concurrent Hairy Cell Leukemia and Metastatic Merkel Cell Carcinoma." Case Reports in Oncological Medicine 2018 (November 14, 2018): 1–6. http://dx.doi.org/10.1155/2018/1736854.

Full text
Abstract:
Hairy cell leukemia (HCL) and Merkel cell carcinoma (MCC) are two rare malignancies with distinct cells of origin. HCL is a lymphoid malignancy of mature B cells, and MCC derives from neuroendocrine cell origin. HCL has a favorable prognosis with most patients achieving long-term remission and potential cure. In contrast, MCC is an aggressive malignancy affecting the skin and can metastasize quickly with a dismal prognosis. Immunocompromised patients, such as those with AIDS, posttransplant, and the elderly, have higher incidences than the general population, suggesting a possible immune mecha
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "B-cell malignancie"

1

BOZZER, SARA. "Preclinical development of targeted-nanoparticles for the treatment of pediatric B-cell malignancies Acute Lymphoblastic Leukemia and Burkitt Lymphoma." Doctoral thesis, Università degli Studi di Trieste, 2022. http://hdl.handle.net/11368/3030999.

Full text
Abstract:
I tumori delle cellule B sono un gruppo eterogeneo di patologie per le quali le opzioni terapeutiche includono chemioterapia e immunoterapia. Nonostante il recente sviluppo di nuove strategie terapeutiche, la maggior parte dei pazienti, tuttavia, sviluppa resistenze o non risponde alle terapie. L'obiettivo di questo progetto di dottorato è, pertanto, lo sviluppo preclinico di un nuovo strumento terapeutico per il trattamento delle neoplasie pediatriche a cellule B. In primo luogo sono state caratterizzate le nanobolle di chitosano (NBs) caricate con AntagomiR-17, sui è stato legato un anticorp
APA, Harvard, Vancouver, ISO, and other styles
2

Runarsson, Gudmundur. "Biosynthesis of leukotriene B₄ in hematological malignancies /." Stockholm, 2005. http://diss.kib.ki.se/2005/91-7140-386-8/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Green, Michael R. "Molecular Profiling of B-Cell Malignancies." Thesis, Griffith University, 2009. http://hdl.handle.net/10072/366546.

Full text
Abstract:
Non-Hodgkin’s lymphoma (NHL) is a group of B-cell malignancies that is the 5th most common cancer in males and the 4th most common cancer in females. Three of the four most common histological subtypes of NHL are Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL) and B-cell Chronic Lymphocytic Leukemia (B-CLL), which together make up over 60% of NHL cases. These diseases vary in both aetiology and aggressiveness, with patient prognosis predicted using indices that rely on biological surrogates in order to predict disease behavior. This results in a large degree of heterogeneity wi
APA, Harvard, Vancouver, ISO, and other styles
4

Mosti, Laura [Verfasser], and Anton [Akademischer Betreuer] Cathomen. "Generation of safe CAR T cells to target B cell malignancies." Freiburg : Universität, 2021. http://d-nb.info/1232174378/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Kokhaei, Parviz. "Preclinical therapeutic vaccination strategies in malignancies with focus on B-cell chronic lymphocytic leukemia /." Stockholm, 2006. http://diss.kib.ki.se/2006/91-7140-595-X/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Martínez-Martín, Sandra. "Targeting MYC in B-cell haematologic malignancies." Doctoral thesis, Universitat Autònoma de Barcelona, 2020. http://hdl.handle.net/10803/670653.

Full text
Abstract:
La importància de la funció de MYC en el càncer (i l’origen del nom de la oncoproteïna) es va descobrir a finals dels 70, amb la identificació de la seqüència del retrovirus aviar causant de la leucèmia mielocítica. Durant més de 40 anys d’investigació, s’ha subratllat la rellevància d’aquesta proteïna en la divisió cel·lular normal i la seva implicació en la transformació tumoral. De fet, una de les primeres connexions entre la sobreexpressió de proto-oncògens (com MYC), reordenaments gènics i el càncer es va fer en el limfoma de Burkitt, la leucèmia mieloide crònica i els plasmacitomes de r
APA, Harvard, Vancouver, ISO, and other styles
7

McCann, Katy. "Immunogenetic analysis of aggressive B-cell malignancies." Thesis, University of Southampton, 2008. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.494386.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Gupta, Sneha Veeraraghavan. "Targeting Protein Metabolism in B-cell Malignancies." The Ohio State University, 2012. http://rave.ohiolink.edu/etdc/view?acc_num=osu1343169973.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Jiménez, Bernal Isabel. "Tumor immune microenvironment in B-cell lymphoid malignancies." Doctoral thesis, Universitat Autònoma de Barcelona, 2020. http://hdl.handle.net/10803/671173.

Full text
Abstract:
El microambient immune tumoral juga un paper fonamental en les etapes inicials de la formació dels tumors i en la progressió d’aquests. Teràpies dirigides a aquest microambient ofereixen noves opcions terapèutiques i també serveixen per a millorar les teràpies actuals enfront de molts càncers, incloent els que afecten les cèl·lules B. No obstant això, són necessàries més recerques per a entendre en major profunditat els mecanismes d’evasió del sistema immune que afavoreixen la progressió dels tumors i dissenyar immunoteràpies més precises. Els nostres principals objectius són aportar noves evi
APA, Harvard, Vancouver, ISO, and other styles
10

Caeser, Rebecca. "Elucidating oncogenic mechanisms in human B cell malignancies." Thesis, University of Cambridge, 2018. https://www.repository.cam.ac.uk/handle/1810/285011.

Full text
Abstract:
This study consists of two pieces of work investigating haematological malignancies; Acute Lymphoblastic Leukaemia (ALL) and Diffuse Large B Cell Lymphoma (DLBCL). Firstly, Pre-B ALL represents the most common paediatric malignancy and despite increasingly improved outcomes for patients, ~ 20% of all patients diagnosed with ALL relapse. Activating mutations in the RAS pathway are common (~50%) and result in hyperactivation of the MAPK pathway. I identified Erk negative feedback control via DUSP6 to be crucial for NRASG12D-mediated pre-B cell transformation and investigated its potential as a t
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "B-cell malignancie"

1

Shokri, Fazel. Expression, production and regulation of rheumatoid factor associated cross-reactive idiotypes in systemic autoimmune diseases and B-cell malignancies. University of Birmingham, 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Perez-Chacon, Gema, Christelle Vincent-Fabert, and Juan M. Zapata, eds. Mouse Models of B Cell Malignancies. Frontiers Media SA, 2021. http://dx.doi.org/10.3389/978-2-88971-896-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Cassidy, Jim, Donald Bissett, Roy A. J. Spence OBE, Miranda Payne, and Gareth Morris-Stiff. Bone and soft tissue malignancies. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199689842.003.0025.

Full text
Abstract:
Haematological malignancies examines the epidemiology, genetics, clinical presentation and classification of these diseases, and presents current treatment approaches for each. First are the acute leukaemias, and the management of acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML). Chronic myeloid leukaemia, its genetics and sensitivity to tyrosine kinase inhibitors, is described. Myelodysplastic syndromes and their management, are followed by chronic lymphoid leukaemias, a large heterogeneous group of diseases, and their treatment. Hodgkin lymphoma, its pathology and presen
APA, Harvard, Vancouver, ISO, and other styles
4

Paggetti, Jérôme, Martina Seiffert, and Etienne Moussay, eds. New Insights into the Complexity of Tumor Immunology in B-cell Malignancies: Disease Biology and Signaling. Frontiers Media SA, 2022. http://dx.doi.org/10.3389/978-2-88974-241-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Paggetti, Jérôme, Etienne Moussay, and Martina Seiffert, eds. New Insights into the Complexity of Tumor Immunology in B-cell Malignancies: Tumor Immunology and Immunotherapy. Frontiers Media SA, 2022. http://dx.doi.org/10.3389/978-2-88974-206-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Purdue, Mark P., Jonathan N. Hofmann, Elizabeth E. Brown, and Celine M. Vachon. Multiple Myeloma. Oxford University Press, 2017. http://dx.doi.org/10.1093/oso/9780190238667.003.0041.

Full text
Abstract:
Multiple myeloma (MM) is the most common malignancy arising from plasma cells, fully differentiated B lymphocytes that produce the immunoglobulin (Ig) heavy- and light-chain molecules comprising antibodies. MM is characterized by an overproduction of clonal plasma cells in the bone marrow and, in most cases, monoclonal secretion of IgG, IgA, or light-chain Ig. Symptoms of end organ damage (hypercalcemia [C], renal failure [R], anemia [A], or bone lesions [B]), herein referred to as CRAB features, were traditionally a necessary criterion for diagnosing MM; however, improvements in treatment and
APA, Harvard, Vancouver, ISO, and other styles
7

Paggetti, Jérôme, Martina Seiffert, and Etienne Moussay, eds. New Insights into the Complexity of Tumor Immunology in B-cell Malignancies: Prognostic and Predictive Biomarkers and Therapy. Frontiers Media SA, 2022. http://dx.doi.org/10.3389/978-2-88974-207-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Hjalgrim, Henrik, Ellen T. Chang, and Sally L. Glaser. Hodgkin Lymphoma. Oxford University Press, 2017. http://dx.doi.org/10.1093/oso/9780190238667.003.0039.

Full text
Abstract:
Hodgkin lymphoma (HL) is a malignant neoplasm of the lymphatic system. The malignant cell clone derives from germinal center B lymphocytes in ~98% of cases, the rest being of T-lymphocyte origin. Each year, HL is diagnosed in roughly 66,000 individuals worldwide. HL is curable with modern therapy in the vast majority of patients, with five-year survival rates exceeding 90% for early-stage disease. However, so far this excellent prognosis has been achieved at the expense of a high incidence of severe long-term treatment complications such as secondary malignancies, and endocrine and cardiovascu
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "B-cell malignancie"

1

Dunlap, Jennifer B., Guang Fan, Nicky Leeborg, and Rita M. Braziel. "B-Cell Malignancies." In Molecular Pathology in Clinical Practice. Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-19674-9_42.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Clout, Ruth, John Murray, Maria Farrell, Daphna Hutt, and Michelle Kenyon. "Cell Therapy, Nursing Implications and Care." In The European Blood and Marrow Transplantation Textbook for Nurses. Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-23394-4_7.

Full text
Abstract:
AbstractOver recent years cellular therapy has seen substantial progress across Europe, particularly cell-based immunotherapy/ immune effector cells (IECs), with the approval of autologous CD19 CAR-T products for patients with relapsed/refractory B-cell malignancies-diffuse large B cell lymphoma, acute lymphoblastic leukaemia (paediatric, teenage and young adult) and mantle cell lymphoma). Whilst this development has delivered benefit to patients with poor risk disease, there is potential for associated toxicities which require careful patient selection, assessment, monitoring, treatment and f
APA, Harvard, Vancouver, ISO, and other styles
3

Barta, Stefan K., Kieron Dunleavy, and Nicolas Mounier. "Diffuse Large B-Cell Lymphoma." In HIV-associated Hematological Malignancies. Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-26857-6_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Pritsch, Otto, and Guillaume Dighiero. "Autoimmunity and B-Cell Malignancies." In Autoimmune Reactions. Humana Press, 1999. http://dx.doi.org/10.1007/978-1-4612-1610-0_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Bacigalupo, Andrea, Arjan Lankester, Fabio Ciceri, and Alice Bertaina. "Haploidentical HCT." In The EBMT Handbook. Springer International Publishing, 2024. http://dx.doi.org/10.1007/978-3-031-44080-9_65.

Full text
Abstract:
AbstractWe will discuss two platforms of haploidentical HSCT(haplo-HSCT): ex vivo T cell depletion and unmanipulated in vivo T-cell depletion. The former has evolved from positive selection of CD34+ cells to selection of CD34+ cells associated with alpha/beta T cell and CD19 B cell depletion. We will outline the outcome of these procedures in children and adults. More recently selective add back of Treg Tcon has also been developed and will be discussed. The second platform is unmanipulated haplo-HSCT: PTCy and ATG have been used alone or in combination to optimize prevention of GvHD. We will
APA, Harvard, Vancouver, ISO, and other styles
6

Mikhaeel, N. George, and Lena Specht. "Diffuse Large B-Cell Lymphoma." In Radiation Therapy in Hematologic Malignancies. Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-42615-0_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Guba, Susan C., and Bart Barlogie. "Stem Cell Transplants for Hematopoietic Malignancies." In Molecular Biology of B-Cell and T-Cell Development. Humana Press, 1998. http://dx.doi.org/10.1007/978-1-4757-2778-4_25.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Tao, Jianguo, and Chih-Chi Andrew Hu. "B Cell Growth, Differentiation and Malignancies." In Hematologic Cancers: From Molecular Pathobiology to Targeted Therapeutics. Springer Netherlands, 2012. http://dx.doi.org/10.1007/978-94-007-5028-9_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Juszczyński, Przemysław, and Krzysztof Warzocha. "Molecular Pathogenesis of Aggressive B-cell Lymphomas." In Molecular Aspects of Hematologic Malignancies. Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-642-29467-9_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Ng, Andrea K. "Primary Mediastinal (Thymic) Large B-Cell Lymphoma." In Radiation Therapy in Hematologic Malignancies. Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-42615-0_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "B-cell malignancie"

1

Kuttikrishnan, Shilpa, Kirti S. Prabhu, Tamam Elimat, et al. "Anticancer Activity of Neosetophomone B, An Aquatic Fungal Secondary Metabolite, Against Hematological Malignancie S." In Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2021. http://dx.doi.org/10.29117/quarfe.2021.0106.

Full text
Abstract:
Cancer is one of the most life threatening diseases, causing nearly 13% death in the worldwide. Leukemia, cancer of the hematopoetic cells is the main cause of cancer death in adults and children. Therapeutic agents used in treatment of cancer are known to have narrow therapeutic window and tendency to develop resistance against some cancer cell lines thus, proposing a need to discover some novel agents to treat cancer. In the present study we investigated the anticancer activity of Neosetophomone B(NSP-B), an aquatic fungal metabolite isolated from Neosetophoma sp against leukemic cells (K562
APA, Harvard, Vancouver, ISO, and other styles
2

Wang, Clara, Haoyang Guo, Hanqin Yang, and Beibo Kang. "Developing CAR-T Therapy for Treating B Cell Malignancies." In International Conference on Biotechnology and Biomedicine. SCITEPRESS - Science and Technology Publications, 2022. http://dx.doi.org/10.5220/0012015100003633.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Weng, Jinsheng, Owhofasa Agbedia, Jingjing Cao, et al. "296 Targeting B-cell malignancies with anti-ROR1 CAR T-cell therapy." In SITC 37th Annual Meeting (SITC 2022) Abstracts. BMJ Publishing Group Ltd, 2022. http://dx.doi.org/10.1136/jitc-2022-sitc2022.0296.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Evmenov, K. S., V. V. Volodin, N. I. Ponomareva, et al. "THE ROLE OF M6A RNA MODIFICATIONS IN THE DEVELOPMENT OF HEPATOCELLULAR CARCINOMA." In XI МЕЖДУНАРОДНАЯ КОНФЕРЕНЦИЯ МОЛОДЫХ УЧЕНЫХ: БИОИНФОРМАТИКОВ, БИОТЕХНОЛОГОВ, БИОФИЗИКОВ, ВИРУСОЛОГОВ, МОЛЕКУЛЯРНЫХ БИОЛОГОВ И СПЕЦИАЛИСТОВ ФУНДАМЕНТАЛЬНОЙ МЕДИЦИНЫ. IPC NSU, 2024. https://doi.org/10.25205/978-5-4437-1691-6-234.

Full text
Abstract:
Epitranscriptomic analysis of M6A-methylation profiles in biopsies of patients with chronic hepatitis B and D showed the presence of differentially methylated M6A sites in RNA in patients at different stages of liver disease. Using targeted m6A RNA methylation, an in vitro study demonstrated the involvement of individual sites in increasing cell malignancy in two models of human hepatoma cells.
APA, Harvard, Vancouver, ISO, and other styles
5

Torralba-Raga, Lamberto, Kasper Melchers, Karen E. Martin, et al. "1146 CAR engineering of adaptive NK cells to guide missing-self responses against B cell malignancies." In SITC 39th Annual Meeting (SITC 2024) Abstracts. BMJ Publishing Group Ltd, 2024. http://dx.doi.org/10.1136/jitc-2024-sitc2024.1146.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Heymann, J., F. Vogiatzi, T. Rösner, et al. "Venetoclax enhances the efficacy of therapeutic antibodies in B-cell malignancies." In 32. Jahrestagung der Kind-Philipp-Stiftung für pädiatrisch onkologische Forschung. Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-1687156.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Cosgun, Kadriye Nehir, Anna Hecht, Xin Yang, et al. "Abstract 4515: Lgr5 mediates positive B-cell selection and is critical for initiation and survival of B-cell malignancies." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-4515.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Morton, Laura T., Anne K. Wouters, Dennis F. Remst, et al. "Abstract A038: Effective rerouting of NK cell cytotoxicity against B-cell malignancies upon TCR gene transfer." In Abstracts: Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; September 30 - October 3, 2018; New York, NY. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/2326-6074.cricimteatiaacr18-a038.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Pasqualucci, Laura. "Abstract IA39: The genetic basis of diffuse large B cell lymphoma." In Abstracts: AACR Special Conference on Hematologic Malignancies: Translating Discoveries to Novel Therapies; September 20-23, 2014; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1557-3265.hemmal14-ia39.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Kraljacic-Culkjovic, Biljana, Tharu Fernando, Rebecca Goldstein, et al. "Abstract B12: EIF4E deregulation drives simultaneous expression of B-cell lymphoma oncogenes." In Abstracts: AACR Special Conference on Hematologic Malignancies: Translating Discoveries to Novel Therapies; September 20-23, 2014; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1557-3265.hemmal14-b12.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "B-cell malignancie"

1

Fitzgerald, David. Anti-CDR3 Therapy for B-Cell Malignancies. Defense Technical Information Center, 2013. http://dx.doi.org/10.21236/ada590597.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Fitzgerald, David. Anti-CDR3 Therapy for B-Cell Malignancies. Defense Technical Information Center, 2014. http://dx.doi.org/10.21236/ada619137.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Xie, Ping. Regulation of Mitochondria Function by TRAF3 in B Lymphocytes and B Cell Malignancies. Defense Technical Information Center, 2014. http://dx.doi.org/10.21236/ada610687.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Wang, Jinjin, H. Zhou, and T. Niu. Risk of Bleeding Associated With Ibrutinib in Patients With B-Cell Malignancies A Systematic Review and Meta-analysis of Randomized Controlled Trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2020. http://dx.doi.org/10.37766/inplasy2020.6.0076.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Zhao, Kangjia, Jiwen Sun, Nanping Shen, et al. Treatment-Related Adverse Events of Chimeric Antigen receptor T-Cell (CAR-T) Cell Therapy in B-cell hematological malignancies in the Pediatric and Young Adult Population: A Systematic Review and Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.7.0034.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'B-cell malignancie' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography